STAGE IV LUNG CANCER AJCC V8
Clinical trials for STAGE IV LUNG CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV LUNG CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV LUNG CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made cancer vaccine shows promise in early trial
⭐️ VACCINE ⭐️ Recruiting nowThis early-phase study tests a personalized vaccine made from unique markers on a patient's own tumor. The goal is to help the immune system fight advanced breast cancer, melanoma, and lung cancer that has not responded to other treatments. About 25 adults with these cancers will…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 28, 2026 23:52 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system attack cancer more effectively. …
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 28, 2026 23:50 UTC
-
New combo therapy aims to extend life in aggressive lung cancer
Disease control Recruiting nowThis study tests whether adding bevacizumab to the standard drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 300 adults with stage IIIB or IV disease will receive either the combination or osimertin…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
New hope for hard-to-treat lung cancer: triple therapy targets resistant tumors
Disease control Recruiting nowThis study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in 50 adults with advanced LKB1-mutant lung adenocarcinoma that no longer responds to standard anti-PD1 treatment. The goal is to see if this triple therapy can sh…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Brain tumor radiation showdown: single dose vs. three doses
Symptom relief Recruiting nowThis study tests whether giving radiation in three smaller doses (fractionated SRS) works better than a single large dose (standard SRS) for people whose cancer has spread to the brain. About 269 adults with certain cancers (like lung, breast, or melanoma) will be randomly assign…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Apr 28, 2026 13:02 UTC
-
Can PET scans predict lung cancer treatment success?
Knowledge-focused Recruiting nowThis study looks at how PET/CT scans change during chemoimmunotherapy and radiation therapy in people with stage IV non-small cell lung cancer. Researchers want to see if these scan changes can help predict how well the cancer responds to treatment. About 80 participants who have…
Matched conditions: STAGE IV LUNG CANCER AJCC V8
Phase: NA • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Apr 28, 2026 13:02 UTC